Document is current
Any future updates will be listed below
-
Authors
Bang, Yuna
Hwang, Sein
Kim, Young Eun
Sung, Dong Kyung
Yang, Misun
Ahn, So Yoon
Sung, Se In
Joo, Kyeung Min
Chang, Yun Sil
-
Funding
Funding for this research was provided by:
Korean Fund for Regenerative Medicine (23C0119L1)
Future Medicine 2030 Project from Samsung Medical Center (SMX1240621)
Korea Health Industry Development Institute (HR22C1363)
- License Information
-
More Information
Article History
Received: 16 April 2024
Accepted: 7 July 2024
First Online: 7 August 2024
Declarations
:
: All animal experimental protocols were reviewed and approved by the Institutional Animal Care and Use Committee (IACUC, Approval number: 20230126004) of the Samsung Biomedical Research Institute, an AAALAC International (Association for Assessment and Accreditation of Laboratory Animal Care)-accredited facility, under the National Institutes of Health Guidelines for Laboratory Animal Care.
: Not applicable.
: The funders had no role in the design of this study, in the collection, analyses, or interpretation of data, in the writing of the manuscript, or in the decision to publish the results. Yun Sil Chang, So Yoon Ahn, and Dong Kyung Sung declare potential conflicts of interest arising from a filed or issued patent titled “Composition for treating infectious diseases comprising exosomes derived from thrombin-treated stem cells. (10-2020-0161582) (18/036,474) (2023-528342) (202180077317.3) (21898556.2)” and “Method for promoting generation of stem cell-derived exosome by using thrombin (10-1643825) (03081223) (6343671) (09982233)” as co-inventors, not as patentees.
